Peter H. Griffith's departure as Chief Financial Officer of Amgen Inc was reported, effective August 31, 2026; the filing names no successor. As of November 6, 2026, Amgen Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 22, 2026 to October 27, 2026, naming 1 appointment and 2 departures (Form 8-K, May 19, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Amgen Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: David W. Gibbs · Role: Director · 8-K, 2026-10-27
- · In / out: Out · Person: Peter H. Griffith · Role: Chief Financial Officer · Effective: 2026-08-31 · 8-K, 2026-05-19
- · In / out: Out · Person: David M. Reese · Role: Executive Vice President · 8-K, 2026-04-22
Amgen Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-22 to 2026-10-27. They name 3 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Amgen Inc files it.
Also on the record for Amgen Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 14, 2026 | Stake report, Schedule 13G, by Capital World Investors | 5.5% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.51% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| September 8, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 10% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Amgen Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Amgen Inc and the records around it.
Amgen Inc elsewhere on the record
Companies that share a holder
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Amgen Inc
Get an email when Amgen Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Amgen Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Amgen Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Amgen Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-27 | In | Director | 8-K, 2026-10-27 | ||
| 2026-05-19 | Out | Chief Financial Officer | 2026-08-31 | 8-K, 2026-05-19 | |
| 2026-04-22 | Out | Executive Vice President | 8-K, 2026-04-22 |
Who leads Amgen Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: David W. Gibbs, appointed (filed 2026-10-27).
- Chief Financial Officer: Peter H. Griffith, departure reported, effective 2026-08-31 (filed 2026-05-19). No successor is named in these filings.
- Executive Vice President: David M. Reese, departure reported (filed 2026-04-22). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Amgen Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Amgen Inc, with the record behind each one.
Find candidates like Director at Amgen IncEvery change, in the filing's words
Appointed: David W. Gibbs, Director
On October 26, 2026, the Board of Directors (the "Board") of Amgen Inc. (the "Company") appointed David W. Gibbs as a director of the Company, effective immediately.
- Mr. Gibbs served as Chief Executive Officer of Yum!
- Brands, Inc., a leading global restaurant company, from 2020 to September 2025 and as a director of Yum!
- Since October 2025, Mr. Gibbs has served as an advisor to Yum!
- Previously, he served as President and Chief Operating Officer of Yum!
- Brands from August 2019 to December 2019; President, Chief Operating Officer and Chief Financial Officer from January 2019 to August 2019; and President and Chief Financial Officer from 2016 to 2018.
- Brands, Mr. Gibbs served as Chief Executive Officer of the Pizza Hut Division from 2015 to 2016, President of Pizza Hut U.S. in 2014, and President and Chief Financial Officer of Yum!
- Mr. Gibbs has served as a director of Under Armour, Inc. since 2021 and is Chair of its Human Capital and Compensation Committee.
- He has served as a director of PepsiCo, Inc. since 2026 and is a member of its Audit Committee.
- Mr. Gibbs holds a bachelor's degree in mathematical science from Johns Hopkins University and a Master of Business Administration degree from the Fuqua School of Business at Duke University.
- Mr. Gibbs will serve as a member of the Board's Audit Committee and its Compensation and Management Development Committee.
- Following the appointment of Mr. Gibbs, the Board will be composed of 13 directors, 12 of whom are independent.
Departing: Peter H. Griffith, Chief Financial Officer, effective 2026-08-31
Retirement of Peter H. Griffith, Chief Financial Officer On May 19, 2026, Amgen Inc. (the "Company") publicly announced that Peter H. Griffith will retire from the role of the Company's Executive Vice President and Chief Financial Officer, effective August 31, 2026.
- In connection with the transition of his role, Mr. Griffith will remain employed as an Executive Vice President, a non-executive officer position from September 1, 2026 until January 31, 2027.
- Mr. Griffith is currently retirement eligible under the Company's plans and policies, and thus upon his departure in January 2027 will receive the retirement benefits provided by the Company's plans and policies, described in the Company's filings, including the Company's proxy statement.
- Appointment of Thomas Dittrich, Executive Vice President and Chief Financial Officer In connection with Mr. Griffith's retirement, on May 19, 2026, the Board of Directors approved hiring Thomas Dittrich, age 62, to serve as Executive Vice President, a non-executive officer position, effective July 1, 2026 through August 31, 2026.
- Effective September 1, 2026, he will serve as Executive Vice President and Chief Financial Officer of the Company.
- Mr. Dittrich will report to Robert A. Bradway, Chairman and Chief Executive Officer.
- Mr. Dittrich will initially be based in Rotkreuz, Switzerland and will be employed by Amgen (Europe) GmbH pursuant to an Employment Offer Agreement with Amgen (Europe) GmbH dated May 16, 2026.
- Mr. Dittrich is expected to relocate to Thousand Oaks, California in connection with his transition to Chief Financial Officer in September 2026.
Departing: David M. Reese, Executive Vice President
On June 30, 2026, Dr. Reese will retire from the role of Executive Vice President.
- On April 22, 2026, Amgen Inc. (the "Company") publicly announced that David M. Reese is retiring from the role of the Company's Executive Vice President and Chief Technology Officer.
- To facilitate the further integration of our science, technology and data and build on the strong alignment of our commercial, medical and policy teams, the responsibilities of this role will be redistributed to James E. Bradner, Executive Vice President, Research and Development, Artificial Intelligence and Data, Murdo Gordon, Executive Vice President, Amgen Global Markets and Policy, and Peter H. Griffith, Executive Vice President and Chief Financial Officer, each effective as of June 1, 2026.
- Dr. Reese will remain employed as an Executive Vice President until his retirement on June 30, 2026.
- At that time, Dr. Reese will be retirement eligible under the Company's plans and policies and, upon his departure from the Company on June 30, 2026, he will receive the retirement benefits set forth in the Company's plans and described in the Company's filings, including the Company's 2026 Proxy Statement.
Tools for this story
Each opens in a new tab, filled in for Amgen Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.